Literature DB >> 16806091

Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia.

Annie Andrieux1, Paul Salin, Annie Schweitzer, Mélina Bégou, Bastien Pachoud, Philippe Brun, Sylvie Gory-Fauré, Pekka Kujala, Marie-Françoise Suaud-Chagny, Gerhard Höfle, Didier Job.   

Abstract

BACKGROUND: Recent data suggest that cytoskeletal defects may play a role in schizophrenia. We previously imitated features of schizophrenia in an animal model by disrupting gene coding for a microtubule-associated protein called STOP. STOP-null mice display synaptic defects in glutamatergic neurons, hyper-dopaminergy, and severe behavioral disorders. Synaptic and behavioral deficits are amended by neuroleptic treatment in STOP-null mice, providing an attractive model to test new antipsychotic agents. We examined the effects of a taxol-related microtubule stabilizer, epothilone D.
METHODS: Mice were treated either with vehicle alone or with epothilone D. Treatment effects on synaptic function were assessed using electron-microscopy quantification of synaptic vesicle pools and electrophysiology in the CA1 region of the hippocampus. Dopamine transmission was investigated using electrochemical assays. Behavior was principally assessed using tests of maternal skills.
RESULTS: In STOP-null mice, treatment with epothilone D increased synaptic vesicle pools, ameliorated both short- and long-term forms of synaptic plasticity in glutamatergic neurons, and had a dramatic beneficial effect on mouse behavior.
CONCLUSIONS: A microtubule stabilizer can have a beneficial effect on synaptic function and behavior, suggesting new possibilities for treatment of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16806091     DOI: 10.1016/j.biopsych.2006.03.048

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  35 in total

1.  Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027.

Authors:  Donna M Barten; Patrizia Fanara; Cathy Andorfer; Nina Hoque; P Y Anne Wong; Kristofor H Husted; Gregory W Cadelina; Lynn B Decarr; Ling Yang; Victoria Liu; Chancy Fessler; Joan Protassio; Timothy Riff; Holly Turner; Christopher G Janus; Sethu Sankaranarayanan; Craig Polson; Jere E Meredith; Gemma Gray; Amanda Hanna; Richard E Olson; Soong-Hoon Kim; Gregory D Vite; Francis Y Lee; Charles F Albright
Journal:  J Neurosci       Date:  2012-05-23       Impact factor: 6.167

2.  Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia.

Authors:  Colm M P O'Tuathaigh; Brian P Kirby; Paula M Moran; John L Waddington
Journal:  Schizophr Bull       Date:  2009-11-24       Impact factor: 9.306

3.  Characterizing the Epothilone Binding Site on β-Tubulin by Photoaffinity Labeling: Identification of β-Tubulin Peptides TARGSQQY and TSRGSQQY as Targets of an Epothilone Photoprobe for Polymerized Tubulin.

Authors:  Adwait R Ranade; LeeAnn Higgins; Todd W Markowski; Nicole Glaser; Dmitry Kashin; Ruoli Bai; Kwon Ho Hong; Ernest Hamel; Gerhard Höfle; Gunda I Georg
Journal:  J Med Chem       Date:  2016-03-17       Impact factor: 7.446

Review 4.  Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies.

Authors:  Carlo Ballatore; Kurt R Brunden; Donna M Huryn; John Q Trojanowski; Virginia M-Y Lee; Amos B Smith
Journal:  J Med Chem       Date:  2012-09-28       Impact factor: 7.446

5.  The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies.

Authors:  Kurt R Brunden; Yuemang Yao; Justin S Potuzak; Nuria Ibarz Ferrer; Carlo Ballatore; Michael J James; Anne-Marie L Hogan; John Q Trojanowski; Amos B Smith; Virginia M-Y Lee
Journal:  Pharmacol Res       Date:  2010-12-14       Impact factor: 7.658

6.  New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia.

Authors:  Avia Merenlender-Wagner; Zeev Shemer; Olga Touloumi; Roza Lagoudaki; Eliezer Giladi; Annie Andrieux; Nikolaos C Grigoriadis; Illana Gozes
Journal:  Autophagy       Date:  2014       Impact factor: 16.016

7.  Paclitaxel C-10 carbamates: potential candidates for the treatment of neurodegenerative tauopathies.

Authors:  Carlo Ballatore; Edward Hyde; Robert F Deiches; Virginia M-Y Lee; John Q Trojanowski; Donna Huryn; Amos B Smith
Journal:  Bioorg Med Chem Lett       Date:  2007-04-25       Impact factor: 2.823

8.  Deletion of the STOP gene, a microtubule stabilizing factor, leads only to discrete cerebral metabolic changes in mice.

Authors:  Ryosuke Hanaya; Estelle Koning; Arielle Ferrandon; Annie Schweitzer; Annie Andrieux; Astrid Nehlig
Journal:  J Neurosci Res       Date:  2008-03       Impact factor: 4.164

9.  Increased stability of microtubules in cultured olfactory neuroepithelial cells from individuals with schizophrenia.

Authors:  Alan S Brown; Karin Borgmann-Winter; Chang-Gyu Hahn; Lorna Role; David Talmage; Raquel Gur; Jacky Chow; Patric Prado; Thelma McCloskey; Yuanyuan Bao; J Chloe Bulinski; Andrew J Dwork
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-10-24       Impact factor: 5.067

10.  Altered microtubule dynamics and vesicular transport in mouse and human MeCP2-deficient astrocytes.

Authors:  Chloé Delépine; Hamid Meziane; Juliette Nectoux; Matthieu Opitz; Amos B Smith; Carlo Ballatore; Yoann Saillour; Annelise Bennaceur-Griscelli; Qiang Chang; Emily Cunningham Williams; Maxime Dahan; Aurélien Duboin; Pierre Billuart; Yann Herault; Thierry Bienvenu
Journal:  Hum Mol Genet       Date:  2015-11-24       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.